Annexon

Annexon, Inc. appointed William “BJ” Jones to its board, leveraging his 30 years of biotech industry experience. Jones's expertise in commercial strategies and product launches is expected to aid Annexon's therapies for neuroinflammatory diseases. He has a history of successful roles in major pharmaceutical companies and currently serves as chief commercial officer at NewAmsterdam Pharma.

Annexon, Inc. appointed William “BJ” Jones to its board, enhancing its leadership with his extensive biotech experience. The company is advancing therapies for neuroinflammatory diseases, presenting at major healthcare conferences, and reporting positive clinical trial results, including for ANX005 in Guillain-Barré Syndrome and ANX007 in Geographic Atrophy. Annexon also announced financial results, key milestones, and leadership expansions to support its late-stage clinical platform.

Annexon, Inc. appointed William “BJ” Jones to its board, leveraging his 30 years in biotechnology for advancing therapies for neuroinflammatory diseases. Jones's expertise is expected to aid in the commercialization of ANX005 and ANX007. Annexon focuses on C1q-targeted treatments for autoimmune, neurodegenerative, and ophthalmic diseases.

Annexon, Inc. presents ANX007, a C1q inhibitor, at Floretina-ICOOR 2024, demonstrating vision protection and photoreceptor preservation in GA. Phase 3 ARCHER II trial actively enrolling, with data expected in 2026.

Complement inhibitors market is growing due to the complement system's role in rare and chronic diseases. Over 40 companies are developing 50+ pipeline inhibitors, including Gefurulimab, ANX005, DNTH103, and others. Recent milestones include Q32 Bio presenting ADX-097 data at ASN Kidney Week 2024 and ReAlta Life Sciences dosing the first patient in a Phase II study of RLS-0071.

ANX007, a non-pegylated Fab designed to block C1q, showed enhanced vision protection and greater EZ preservation in less advanced GA patients, according to Phase 2 ARCHER study data presented at AAO 2024. ANX007 demonstrated significant vision and photoreceptor protection, with a more pronounced effect in patients with less advanced disease. Pivotal Phase 3 ARCHER II data is expected in H2 2026.

ANX007, a non-pegylated antigen-binding fragment, demonstrated enhanced vision protection and greater photoreceptor preservation in patients with less advanced geographic atrophy (GA) due to dry age-related macular degeneration (AMD). The Phase 2 ARCHER study results were presented at the AAO 2024 annual meeting, showing ANX007's potential for earlier intervention in neurodegenerative diseases. Pivotal Phase 3 ARCHER II data is expected in the second half of 2026.

The 2024 American Academy of Ophthalmology meeting in Chicago will feature presentations on clinical trial data from Alkeus Pharmaceuticals, Annexon, Inc., Atsena Therapeutics, Avirmax Biopharma, Inc., Beacon Therapeutics, Belite Bio, Eyenovia, LENZ Therapeutics, Nanoscope Therapeutics, Inc., and ZEISS Medical Technology.

Annexon, Inc. announced new ANX007 analyses from the Phase 2 ARCHER trial in geographic atrophy (GA) at the AAO 2024 annual meeting and Eyecelerator conference. ANX007, a non-pegylated Fab designed to block C1q locally in the eye, demonstrated significant vision protection and photoreceptor preservation in the fovea region. Phase 3 data from the ongoing ARCHER II pivotal program is expected in the second half of 2026.